Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Growth in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 76,200 shares, an increase of 150.7% from the November 30th total of 30,400 shares. Based on an average trading volume of 559,900 shares, the short-interest ratio is presently 0.1 days.

Astellas Pharma Stock Performance

Shares of OTCMKTS ALPMY opened at $9.72 on Friday. The stock has a market cap of $17.59 billion, a PE ratio of 46.29 and a beta of 0.33. The company has a debt-to-equity ratio of 0.26, a current ratio of 0.90 and a quick ratio of 0.72. The firm has a fifty day moving average price of $10.62 and a 200-day moving average price of $11.01. Astellas Pharma has a 1 year low of $9.15 and a 1 year high of $13.14.

Astellas Pharma (OTCMKTS:ALPMY) last issued its earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share (EPS) for the quarter. Astellas Pharma had a return on equity of 10.33% and a net margin of 3.26%. The company had revenue of $3.11 billion for the quarter. Equities analysts anticipate that Astellas Pharma will post 0.61 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.